Barclays Reaffirms Their Hold Rating on Insulet (PODD)

In a report released today, Matt Miksic from Barclays maintained a Hold rating on Insulet (PODD – Research Report), with a price target of $266.00. The company’s shares closed last Friday at $310.67.

Protect Your Portfolio Against Market Uncertainty

• Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
• Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.

Miksic covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, LivaNova, and Abbott Laboratories. According to TipRanks, Miksic has an average return of 6.6% and a 60.19% success rate on recommended stocks.

In addition to Barclays, Insulet also received a Hold from Stifel Nicolaus’s Mathew Blackman in a report issued on May 9. However, on the same day, Oppenheimer maintained a Buy rating on Insulet (NASDAQ: PODD).

The company has a one-year high of $312.16 and a one-year low of $160.19. Currently, Insulet has an average volume of 895.8K.